Preoperative Anxiety — Preoperative Anxiety's Incidence and Related Factors in Surgical Patients
Citation(s)
Fan JM, Chen XQ, Du JZ Prenatal stress, anxiety and depression: a mechanism involving CRH peptide family. Neuro Endocrinol Lett. 2014;35(6):429-39. Review.
He W, Zhou Q, Yu S, Cai D, Wang Q, Zhang X, Huang WQ [Mechanism on atrial natriuretic peptide receptor in anti-anxiety with acupuncture based on its tranquilizing effect]. Zhongguo Zhen Jiu. 2015 Jan;35(1):101-4. Review. Chinese.
Lieb K, Fiebich BL, Berger M [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?]. Nervenarzt. 2000 Sep;71(9):758-61. Review. German.
Maki Y [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors]. Hokkaido Igaku Zasshi. 2001 May;76(3):133-42. Review. Japanese.
Matsumoto K, Puia G, Dong E, Pinna G GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress. 2007 Ma
Micó JA, Prieto R Elucidating the mechanism of action of pregabalin: a(2)d as a therapeutic target in anxiety. CNS Drugs. 2012 Aug 1;26(8):637-48. doi: 10.2165/11634510-000000000-00000. Review.
O'Donovan A, Slavich GM, Epel ES, Neylan TC Exaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of aging. Neurosci Biobehav Rev. 2013 Jan;37(1):96-108. doi: 10.1016/j.neubiorev.2012.10.013. Ep
Yamauchi M, Hiraoka S, Imanishi T [Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2006 Nov;26(5-6):193-8. Review. Japanese.
Preoperative Anxiety's Incidence and Related Factors in Surgical Patients
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
